 NORTH BILLERICA, Mass. and HAYWARD, Calif., Sept. 13, 2021 GLOBE NEWSWIRE -- Lantheus Holdings, Inc. NASDAQ: LNTH Lantheus and RefleXion Medical, Inc., today announced a development and commercialization collaboration to evaluate the use of piflufolastat F 18, Lantheus prostate-specific membrane antigen PSMA-targeted positron emission tomography PET imaging agent, to enable real-time therapeutic guidance of biology-guided radiotherapy1 BgRT in prostate cancer using the RefleXion X1TM platform. 